Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PI4KA | P42356 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.36 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 7/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 7/20 | 0.35 |
| ▸ | MAT2A | P31153 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23290158 | 0.99 | PIK3CD (0.40) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL23290362 | 0.88 | PIK3CD (0.38) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| Hydrochloric Acid SCHEMBL23803114 | 0.87 | PIK3CD (0.38) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL23290679 | 0.83 | MEN1 (0.51) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL23290232 | 0.82 | PIK3CD (0.42) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL23290495 | 0.81 | PIK3CD (0.40) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL23290580 | 0.81 | PIK3CD (0.40) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| Hydrochloric Acid SCHEMBL23290311 | 0.80 | PIK3CD (0.39) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL23290275 | 0.80 | MEN1 (0.47) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| Hydrochloric Acid SCHEMBL23290175 | 0.79 | MEN1 (0.46) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112805280-B | Heteroaryl compounds for the treatment of huntington's disease | PTC医疗公司 | 2024-12-06 | — | — | CN | claimed |
| US-12139499-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2024-11-12 | — | — | US | claimed |
| EP-3814345-B1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-09-25 | — | — | EP | claimed |
| US-20210284660-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2021-09-16 | — | — | US | claimed |
| CN-112805280-A | Heteroaryl compounds for the treatment of huntington's disease | PTC医疗公司 | 2021-05-14 | — | — | CN | claimed |
| EP-3814345-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | claimed |
| US-12139499-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| EP-3814345-B1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20210284660-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210284660-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2021-09-16 | — | — | US | disclosed |
| EP-3814345-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139499-B2 | Heteroaryl compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | PIK3CD 4000/4885PIK3CA 3279/4885PIK3CB 3336/4885 |
| US-20210284660-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | PIK3CD 4000/4885PIK3CA 3279/4885PIK3CB 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.